Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) reported fourth quarter and full year 2022 financial results, achieving revenue of $6.8 million for the year, up from $1.5 million in 2021. In Q4 2022, revenue was $1.424 million, compared to $0.436 million in Q4 2021. The net loss for the year was $73.164 million, or $1.04 per share, an increase from $64.851 million or $17.57 per share in the previous year. The company ended the year with $117.472 million in cash. 2023 guidance estimates revenue between $10 to $14 million with a cash burn of $40 to $45 million. Significant achievements included FDA clearances and the installation of 35 commercial systems.

Positive

• Revenue growth from $1.496 million in 2021 to $6.814 million in 2022.
• Achieved multiple FDA clearances and 35 new commercial system installations.
• Current cash reserves of $117.472 million, extending cash runway through 2025.

Negative

• Net loss increased to $73.164 million in 2022 compared to $64.851 million in 2021.
• 2023 cash burn guidance of $40 to $45 million indicates significant expenditure.

GUILFORD, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™ today announced fourth quarter and full year 2022 financial results and provided a business update.

“We made measurable progress at Hyperfine over the past year. We delivered $6.8 million in revenue in 2022, received multiple FDA clearances and international approvals, including CE Marking, in recent months, and saw a large number of publications and presentations on the clinical value of Swoop published and presented via major journals and meetings. We also implemented important measures to right size our business and extend our cash runway through the end of 2025, ending the year with a healthy balance sheet. These achievements lay the foundation for strong forward growth,” said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. “We believe the opportunity for Hyperfine to transform access to MRI scans across clinical uses and sites of service is incredibly compelling. Our team is dedicated to expanding commercial placements while focusing on additional innovation and clinical evidence. We look forward to growing our impact in the field of medical imaging and diagnostics.”

Recent Achievements

• Installed 35 commercial systems for the full year 2022.
• Multiple FDA clearances for AI-powered software upgrades to support improved image quality.
• 15 clinical publications, including Scientific Reports, Science Advances, and Radiology, and 50 peer-reviewed presentations at key neuro and imaging meetings.
• Strengthened partnership with the Bill & Melinda Gates Foundation with a purchase order through Kings College London for 20 additional Swoop systems.
• Restructured and right-sized organization to extend Hyperfine, Inc.’s cash runway through the end of 2025.
  

Fourth Quarter 2022 Financial Results

• Revenues for the fourth quarter of 2022 were $1.424 million, compared to $0.436 million in the fourth quarter of 2021.
• Gross margin for the fourth quarter of 2022 was $0.300 million, compared to $(0.453) million in the fourth quarter of 2021.
• Research and development expenses for the fourth quarter of 2022 were $5.219 million, compared to $8.893 million in the fourth quarter of 2021.
• Sales, general, and administrative expenses for the fourth quarter of 2022 were $8.710 million, compared to $16.741 million in the fourth quarter of 2021.
• Net loss for the fourth quarter was $13.059 million, equating to a net loss of $0.19 per share, as compared to a net loss of $26.085 million, or a net loss of $13.79 per share, for the same period of the prior year.
  

Full Year 2022 Financial Results

• Revenues for the full year 2022 were $6.814 million, compared to $1.496 million in 2021.
• Gross margin for the full year 2022 was $0.907 million, compared to $(1.167) million in 2021.
• Research and development expenses for the full year 2022 were $28.156 million, compared to $25.842 million in 2021.
• Sales, general, and administrative expenses for full year 2022 were $46.625 million, compared to $37.859 million in 2021.
• Net loss for the full year was $73.164 million, equating to a net loss of $1.04 per share, as compared to a net loss of $64.851 million, or a net loss of $17.57 per share, for the prior year.
• Cash and cash equivalents totaled $117.472 million as of December 31, 2022.

2023 Financial Guidance

• Management expects revenue for the full year 2023 to be $10 to $14 million.
• Management expects cash burn for the full year to be $40 to $45 million.

Conference Call

Hyperfine, Inc. will host a conference call at 1:30 p.m. PT/ 4:30 p.m. ET on Tuesday, March 21, 2023, to discuss its fourth quarter and full year 2022 financial results and provide a business update. Those interested in listening should register online by visiting https://investors.hyperfine.io/. and clicking on News & Events. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived audio webcast will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/

About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System

Hyperfine, Inc. (NASDAQ: HYPR) is the groundbreaking medical technology company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a bedside magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand and Pakistan.

The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging, and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine, Inc. (“the Company”)’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about the Company’s financial and operating results, the Company’s commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the Company’s ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Contact
Marissa Bych
Gilmartin Group LLC
marissa@gilmartinir.com

HYPERFINE, INC. AND SUBSIDIARIES
COMBINED AND CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)

		December 31,				December 31,
		2022				2021
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	117,472			$	188,498
Restricted cash			771				2,662
Accounts receivable, net			2,103				553
Unbilled receivables			454				91
Inventory			4,622				4,310
Prepaid expenses and other current assets			3,194				1,357
Due from related parties			48				14
Total current assets		$	128,664			$	197,485
Property and equipment, net			3,248				3,753
Other long term assets			2,139				1,235
Total assets		$	134,051			$	202,473
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	678			$	2,248
Deferred grant funding			771				2,662
Deferred revenue			1,378				730
Due to related parties			—				1,981
Accrued expenses and other current liabilities			5,976				8,115
Total current liabilities		$	8,803			$	15,736
Long term deferred revenue			1,526				510
Total liabilities		$	10,329			$	16,246
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Class A Common stock, $.0001 par value; 600,000,000 shares authorized; 55,622,488 and 55,277,061 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively			5				5
Class B Common stock, $.0001 par value; 27,000,000 shares authorized; 15,055,288 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively			2				2
Additional paid-in capital			333,199				322,540
Accumulated deficit			(209,484	)			(136,320	)
Total stockholders' equity		$	123,722			$	186,227
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$	134,051			$	202,473

HYPERFINE, INC. AND SUBSIDIARIES
COMBINED AND CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(Unaudited)

		Three months ended December 31,								Year ended December 31,
		2022				2021				2022				2021
Sales
Device		$	941			$	194			$	5,246			$	715
Service			483				242				1,568				781
Total sales		$	1,424			$	436			$	6,814			$	1,496
Cost of sales
Device		$	720			$	638			$	4,231			$	2,058
Service			404				251				1,676				605
Total cost of sales		$	1,124			$	889			$	5,907			$	2,663
Gross margin			300				(453	)			907				(1,167	)
Operating Expenses:
Research and development		$	5,219			$	8,893			$	28,156			$	25,842
General and administrative			5,836				12,149				32,406				27,497
Sales and marketing			2,874				4,592				14,219				10,362
Total operating expenses			13,929				25,634				74,781				63,701
Loss from operations		$	(13,629	)		$	(26,087	)		$	(73,874	)		$	(64,868	)
Interest income		$	558			$	5			$	761			$	18
Other income (expense), net			12				(3	)			(51	)			(1	)
Loss before provision for income taxes		$	(13,059	)		$	(26,085	)		$	(73,164	)		$	(64,851	)
Provision for income taxes			—				—				—				—
Net loss and comprehensive loss		$	(13,059	)		$	(26,085	)		$	(73,164	)		$	(64,851	)
Net loss per common share attributable to common stockholders, basic and diluted		$	(0.19	)		$	(13.79	)		$	(1.04	)		$	(17.57	)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted			70,588,368				1,892,208				70,449,191				3,690,523

HYPERFINE, INC. AND SUBSIDIARIES
COMBINED AND CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
(Unaudited)

		Three months ended December 31,								Year ended December 31,
		2022				2021				2022				2021
Cash flows from operating activities:
Net loss		$	(13,059	)		$	(26,085	)		$	(73,164	)		$	(64,851	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			261				337				1,015				726
Stock-based compensation expense			1,793				3,770				10,652				6,901
Write-off of other assets - related party			—				984				—				984
Other			85				59				91				85
Changes in assets and liabilities
Accounts receivable			599				387				(1,550	)			(379	)
Unbilled receivables			1,021				(43	)			(363	)			(91	)
Inventory			(620	)			(1,603	)			(312	)			(2,667	)
Prepaid expenses and other current assets			(1,398	)			2,243				(1,837	)			(666	)
Due from related parties			(48	)			(1	)			(34	)			1,451
Other assets - related party			—				102				—				260
Prepaid inventory			(281	)			—				(281	)			—
Other long term assets			(694	)			(587	)			(632	)			(1,201	)
Accounts payable			(48	)			(2,487	)			(1,570	)			1,436
Deferred grant funding			(488	)			(805	)			(1,891	)			1,052
Deferred revenue			566				126				1,664				1,082
Due to related parties			(61	)			647				(1,981	)			1,845
Accrued expenses and other current liabilities			(2,973	)			4,821				(2,146	)			6,851
Net cash used in operating activities		$	(15,345	)		$	(18,135	)		$	(72,339	)		$	(47,182	)
Cash flows from investing activities:
Purchases of property and equipment			(158	)			(975	)			(585	)			(2,711	)
Net cash used in investing activities		$	(158	)		$	(975	)		$	(585	)		$	(2,711	)
Cash flows from financing activities:
Proceeds from exercise of stock options			5				35				7				1,497
Proceeds from issuance of Series D convertible preferred stock			—				—				—				30,468
Stock issuance costs related to Series D convertible preferred stock			—				—				—				(7	)
Repayment of notes payable			—				(178	)			—				(178	)
Investment from 4Bionics, LLC			—				—				—				3,516
Net proceeds from equity infusion from the Business Combination			—				141,471				—				141,471
Net cash provided by financing activities		$	5			$	141,328			$	7			$	176,767
Net (decrease) increase in cash and cash equivalents and restricted cash			(15,498	)			122,218				(72,917	)			126,874
Cash, cash equivalents and restricted cash, beginning of period			133,741				68,942				191,160				64,286
Cash, cash equivalents and restricted cash, end of period		$	118,243			$	191,160			$	118,243			$	191,160
Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position
Cash and cash equivalents		$	117,472			$	188,498			$	117,472			$	188,498
Restricted cash			771				2,662				771				2,662
Total cash, cash equivalents and restricted cash		$	118,243			$	191,160			$	118,243			$	191,160
Supplemental disclosure of cash flow information:
Cash received from exchange of research and development tax credits		$	—			$	50			$	131			$	374
Supplemental disclosure of noncash information:
Write-off of notes receivable		$	—			$	—			$	90			$	—
Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination		$	—			$	3,000			$	—			$	3,000

FAQ

What were Hyperfine's revenue results for 2022?

Hyperfine reported revenue of $6.8 million for the full year 2022, compared to $1.5 million in 2021.

What is the expected revenue for Hyperfine in 2023?

Management expects Hyperfine's revenue for 2023 to be between $10 to $14 million.

How much cash does Hyperfine have as of December 31, 2022?

Hyperfine ended 2022 with $117.472 million in cash and cash equivalents.

What was Hyperfine's net loss for the fourth quarter of 2022?

The net loss for the fourth quarter of 2022 was $13.059 million, or $0.19 per share.

What significant achievements did Hyperfine make in 2022?

Hyperfine achieved multiple FDA clearances and installed 35 new commercial systems in 2022.